By

Luke Timmerman

11
Nov
2020

Creating the Future of Microbiome-Based Therapies: Simba Gill on The Long Run

Today’s guest on The Long Run is Simba Gill. Simba is the CEO of Cambridge, Mass.-based Evelo Biosciences. Evelo is part of a new generation of biotech companies seeking to make medicines based on new understanding of the microbiome. The science here is fascinating. Evelo’s drug candidates are biologics designed to be taken orally, to act directly in the gut,...
Read More
5
Nov
2020

Reflections from a Wisconsin Boy

My first real journalism job flashed to mind this week. It was 1998-1999. I was a kid reporter fresh out of the University of Wisconsin. My job was to cover Dane County government for The Capital Times, the progressive newspaper in Madison. Dane County had about 400,000 people. Half lived in the beating liberal heart of the City of Madison...
Read More
26
Oct
2020

Machine Learning for Drug Discovery: Daphne Koller on The Long Run

Today’s guest on The Long Run is Daphne Koller. Daphne is the CEO of South San Francisco-based insitro. The company is seeking to develop a new platform for drug discovery that leans on a combination of wet labs and machine learning algorithms to spot new biological targets for drug discovery. Artificial intelligence and machine learning have been stirring imaginations in...
Read More
22
Oct
2020

Remdesivir’s FDA Approval, Moderna Fully Enrolls & FDA Wrestles With Trust

Catch up on the main events of the week in biotech with Frontpoints. The FDA issued a surprising approval – not another watered-down Emergency Use Authorization – to Gilead Sciences for remdesivir (Veklury) its antiviral against COVID-19. The antiviral, designed to stop the SARS-CoV-2 virus from copying itself, is now the first treatment fully approved by the FDA against this...
Read More
28
Sep
2020

Small Molecules Against RNA Targets: Jennifer Petter on The Long Run

Today’s guest on The Long Run is Jennifer Petter. She is the founder and chief scientific officer of Waltham, Massachusetts-based Arrakis Therapeutics. Jennifer is a medicinal chemist who has spent her career thinking about how to make small molecules with all the classic Lipinski “Rule of 5” characteristics against protein targets. Five years ago, when she was looking for a...
Read More
10
Sep
2020

Industry and Academia Take a Stand for Science

Science is under attack. The FDA and the CDC have seen their credibility tarnished, largely because of the relentless pressure, and lies, of certain political leaders. The pharmaceutical industry, built on a bedrock of science, knows darn well that the whole business will come crumbling down if the world continues indulging in this bottomless cynicism and nihilism that says everything...
Read More
8
Sep
2020

Becoming a Biotech VC: Otello Stampacchia on The Long Run

Today’s guest on The Long Run is Otello Stampacchia. He’s the founder and managing director of Omega Funds. Otello started Omega in 2004, and it’s now on Fund VI. Based in Boston, Omega has $1 billion under management, and invests in a wide variety of biotech companies – early stage, later stage, American, European, oncology, immunology, rare disease. There’s a...
Read More